reason report
bottom line believ pacira exparel non-opioid
post-op pain manag continu grow driven
 commerci collabor potenti label expans
nerv block sale
believ well understood investor long-term growth
may impact entri heron op potenti
hour easier administr instil vs infiltr rate pacira
stock market perform mp price target
believ exparel growth next year could
come increas penetr orthoped surgeri
op collabor nerv block approv expand indic
drive usag among anesthesiologist risk-adjust sale
increas penetr soft tissu market addit ph
data howev base interview medacorp physician
studi posit impact long-term growth
believ risk-reward balanc current level
next month expect sale growth exparel posit
stock like off-set potenti posit data
phase studi addit look manag
leverag balanc sheet explor busi develop
deriv price target base dcf
forecast cash flow use wacc
dcf use wacc
termin growth rate
net debt total capit
per share exclud short-term
compani inform leerink partner llc research
revenu
pleas refer page import disclosur price chart analyst certif
pacira initi coverag market perform rate pt
pacira exparel grow near term potenti face
competit heron outer year
expect sale growth
mainli due collabor in-
line consensu slow outer year
due potenti competit heron
sale growth near term could come
increas penetr orthoped surgeri
collabor
nerv block approv expand indic
drive usag among anesthesiologist
risk-adjust sale
increas penetr soft tissu
market addit ph data
long-term growth may impact entri
heron better clinic profil longer
efficaci easier administr
pt base dcf forecast cash
flow use wacc
exparel sale see near-term upsid
salesforc logarithm larger pacira salesforc
adcom nerv block indic feb
ph readout c-section studi
exparel get approv nerv block
ph studi success
limit impact collabor
potenti competit heron
near-term overhang upcom adcom nerv block howev
collabor drive growth exist indic
logarithm larger- pacira state exact number rep take part co-promot competitor healthcar confer sept
leerink estim factset note market cap million average volum thousand
vs vs inc
pacira lead product exparel drive total revenu
pacira develop product leverag proprietari depofoam
compani chang name june depotech corp
ipo feb
suspens consist bupivacain encapsul depofoam
approv octob
also sell bupivacain liposom inject suspens product
approv single-dos infiltr surgic site non-
expans label includ nerv block
complet respons letter march
adcom schedul feb
compani report leerink estim
downsid
compani report factset leerink estim
revenu in-lin con
expect grow
gross margin increas modestli
ep slightli consensu
cash short-term invest debt
grow
enabl manag explor busi develop
risk-adjust nerv block revenu ahead nerv
block adcom pdufa feb april respect
c-section result posit drive penetr soft
forecast cash flow
use wacc termin growth rate reflect eros
deriv valuat use dcf
outer year potenti competit
number setback exparel approv across variou
indic drove high rang
resolut exparel warn letter
fda
exparel nerv
adcom nerv
doj subpoena exparel
factset compani report
invest thesi believ stock current level reflect
exparel sale grow in-lin expect
differ
exparel
nerv
believ likelihood
two fail studi tka
exparel receiv expand
indic nerv block
intercost believ chanc
approv
pacira satisfi fda request
pk data hour posit
addit nb studi conduct
us upper/low extrem procedur
posit
forecast sale grow
forecast exparel sale reach
sale believ current
consensu number appropri reflect
growth potenti exparel
driven
increas penetr
soft tissu market
compani report leerink estim pacira press releas
exparel offer longer pain control vs bupivacain hour
bupivacain
use
decad
exparel
pain relief
mode administr
opioid typic follow
reduc avoid opioid
cover drg
cover drg
sourc packag insert exparel bupivacain price rx compani report
exparel offer longer pain control bupivacain may
competit heron start
dilut possibl
durat pain relief
studi medacorp
inject depend
size incis
topic appli
smear directli
tka
may longer efficaci simpler administr
compani report leerink estim
market local anesthet larg unmet need
longer-act pain control
surgeri us
local anesthet use
surgeri
pain manag surgeri us
pain management non-otc
pain management over-the-counter
remain unmet need
longer durat pain
control opioid avoid
opioid crisi continu mount
cdc issu guidelin
declar public
gener local
use opioid remain often
necessari current option
hospit remain incentiv
shorten hospit length stay
exparel demonstr
longer durat efficaci
exparel approv sinc infiltr surgic
site make headway
bupivacain infiltr
far current gain share
auc nr
median time
first use
less pain
hr
durat pain control
base discuss medacorp kol ideal
durat analgesia hour
exparel studi support
efficaci sever medacorp kol note clinic
practic last closer hour
expect exparel grow risk-adjust
exparel sale indic
approv use nerv block drive use among anesthesiologist
increas penetr soft tissu addit ph data
increas penetr orthoped surgeri collabor
soft tissu procedur pacira run sever studi
gener addit data support share growth
pacira target key
number surgeri us
expect
next
expect mid-
share
market
pacira salesforc
remain focus
salesforc focu
grow share
rep focu
promot soft tissu
posit
procedur
discuss pacira manag compani report leerink estim
expect collabor start drive growth
increas sale
effort behind exparel
rep across vertic
train deploy field
rep
incentiv sell
incent link
exparel offer
addit detail
portfolio
product sell
provid access
new account
alreadi use
train tool help
msl focu
collabor
center
nerv block data mix near-term uncertainti around
fda adcom decis risk-adjust number
background compani origin submit studi femor nerv block posit intercost
nerv block fail receiv march ask data upper extrem longer patient
follow-up snda accept fda oct includ posit studi upper/low extrem
 compar studi hand/wrist foot/ankl pk data hr dose adcom
schedul feb
fail stat sig one center
deviat studi protocol studi
posit exclud site
hr day post
fail stat sig result
like due poor studi adher
vari techniqu
posit auc nr lower
estim chanc
two fail
deviat protocol
exclud site studi
efficaci result
countri
patient us
conduct us
procedur check box
minimum posit
studi requir approv
three driver help exparel gain traction
orthoped surgeri near term
number
leerink estim orthoped nation registri procedur
upside/downsid scenario pacira
peak sale
sale
penetr limit
competit htx-
compani report factset leerink estim
exparel
current
compani report leerink estim
rank pacira along stock select criteria
near term catalyst may meaning /- impact stockposit sale growth ad com decis neg data competitor upside/ downsid leerink valuat estim rel stock priceour dcf analysi point valuat in-lin current valuesscaleupside/ downsid leerink revenu ep estim rel consensusw in-lin consensu revenu thru assum slowdown ramp outer year due competit sheet flexibility leverag balanc sheet capit deploy base metric chang leverag ratio chang yieldnet debt/ebitda ratio significantli improv enabl manag explor busi develop opportun inc
heron data
neg
adjust
compani report leerink estim
knee hip
risk invest thesi
potenti downsid risk estim
nerv block adcom feb may conclud nerv block approv base
mix studi result two fail nerv block studi intercost tka
may better clinic efficaci nerv block compar exparel
potenti upsid risk estim
nerv block indic approv april
signific delay ph studi fail
potenti downsid risk estim
may outperform soft tissu procedur
potenti upsid risk estim
ph soft tissu studi c-section breast reconstruct colorect may
highli success result faster market share expect
potenti downsid risk estim
heron may decid co-promot stay competit
potenti upsid risk estim
 rep may abl success leverag broad reach establish
relationship hospit surgeon result faster growth anticip
compani report leerink estim medacorp physician call
presid ceo
dave stack presid ceo pacira sinc decemb
previous presid ceo medicin compani
follow presid gener manag innovex
mr stack also held variou senior level commerci posit
roch lab almost year
mr stack hold degre pharmaci albani colleg
biolog siena colleg
charl reinhart join pacira cfo
previous cfo covi archimed pharmathen
also held sever senior manag posit within millennium
pharmaceut cephalon
mr reinhart earn bachelor scienc degre lehigh
univers wharton school univers
pennsylvania also
dr scott braunstein join pacira
practic physician investor advis biotechnolog
pharmaceut compani year
dr braunstein earn medic degre albert einstein colleg
medicin complet intern medic resid cornel
number except per share data
royalti
figur except per share data
collabor licens develop revenu
sourc press releas transcript sec file
number except per share data
prepaid expens
current portion defrer revenu
accumul comprehens loss
number except per share data
adjust reconcil ni net cash oper
amort unfavor leas oblig debt issuanc cost
amort debt discount
loss dispos fix asset
loss extinguish debt
decreas increas work capit
purchas fix asset capital-expenditure
purchas invest
sale invest
payment conting consider
net invest
proce exercis stock option warrant
proce share issu employe stock purchas plan
convers princip equiti compon convert senior
net financ
net chang equival
number except per share data
chang work capit
figur except per share data
procedur
procedur
procedur
procedur
figur except per share data
procedur
procedur
procedur
figur except per share data
procedur
procedur
procedur
procedur
figur except per share data
total procedur exparel
